SciSparc (SPRC)announced the publication of a Japanese divisional patent. The patent application introduces a novel pharmaceutical combination of paracetamol and palmitoylethanolamide that may enhance pain relief and fever relief with lower doses and fewer side effects compared to paracetamol monotherapy, with potential for safer and more effective treatment for millions worldwide.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRC:
- SciSparc Ltd. Announces Annual General Meeting for June 2025
- SciSparc and Clearmind Secure European Patent for Cocaine Addiction Therapy
- SciSparc, Clearmind announce publication of European patent
- Clearmind Medicine announces publication of European patent application
- Biotech Alert: Searches spiking for these stocks today
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue